

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/695,516	10/29/2003	John D. Wagstaff	2314-271	8073
6449 75	90 03/13/2006		EXAMINER	
ROTHWELL, FIGG, ERNST & MANBECK, P.C.			HARLE, JENNIFER I	
1425 K STREET, N.W. SUITE 800 WASHINGTON, DC 20005			ART UNIT .	PAPER NUMBER
			1654	

DATE MAILED: 03/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)				
Office Action Summary		10/695,516	WAGSTAFF ET AL.				
		Examiner	Art Unit				
		Jennifer I. Harle	1654				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SH WHIC - Exter after - If NO - Failu Any (ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING Donsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timwill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
2a)□	Responsive to communication(s) filed on 29 O This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	s action is non-final. nce except for formal matters, pro					
Dispositi	on of Claims						
5) 6) 7)	Claim(s) <u>1-26</u> is/are pending in the application 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-26</u> are subject to restriction and/or one	wn from consideration.					
Applicati	on Papers						
10)□	The specification is objected to by the Examine The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the Eddrawing(s) be held in abeyance. See tion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority u	ınder 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4)					
3) 🔲 Inforr	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date		ratent Application (PTO-152)				

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 15-16 and 2-3, drawn to a method of treating acute post trauma pain in an individual, classified in class 514, subclass 13.
 - II. Claims 18 and 5, drawn to a method of treating chronic pain resulting from cancer, classified in class 514, subclass 13.
 - III. Claims 19 and 6, drawn to a method of treating chronic pain resulting from neuropathic pain, classified in class 514, subclass 13.
 - IV. Claims 20 and 7, drawn to a method of treating chronic pain resulting from inflammation, classified in class 514, subclass 13.
- 2. Claims 17 and 4 link inventions II through IV.
- 3. Claims 14 and 21-26 and 1 and 8-13 link(s) inventions I-IV.
- 4. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims 17 and 4 with respect to inventions II-IV and claims 14 and 21-26 and 1 and 8-13 with respect to inventions I-IV. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 Claims that require all the limitations of an allowable linking claim will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.

Page 3

Art Unit: 1654

Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim(s) including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

- 5. Inventions I, II, III, and IV are directed to related methods of treating pain. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case, the methods as claimed have different patient populations, different modes/mechanisms of action and different desired results, i.e., a patient with neuropathic pain would not necessarily have cancer nor would it be post traumatic.
- 6. Searching the inventions of Groups I -IV together would impose serious search burden. In the instant case, the search for the method of treating acute pain/post trauma and the method of treating chronic pain that results from any of cancer or neuropathic pain or inflammation are not coextensive. Groups I-IV encompass different idiopathies, keywords, types of diseases that would be searched, which are not required for the search of other groups. Prior art which teaches the one method may be novel or unobvious for another method. The searches may require

Art Unit: 1654

different databases, search strategies, formulations and the like. Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

7. Claims 1-26 are generic to a plethora of patentably distinct species including for example CGX-1160 or CGX-1063 as set forth in the specification. The species are independent or distinct because they have no common core structure disclosed as essential for utility and are structurally distinct from one another and the search of one species would not necessarily lead to the discovery of another species. Applicant is required under 35 U.S.C. 121 to elect a single specific (each element of the compound is to be defined) disclosed species, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Application/Control Number: 10/695,516 Page 5

Art Unit: 1654

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer I. Harle whose telephone number is (571) 272-2763. The examiner can normally be reached on Monday through Thursday, 6:30 am to 5:00 pm,.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ennifer I. Harle

Examiner

Art Unit 1654

February 28, 2006